| Literature DB >> 30733969 |
Zhong Xin1, Lin Hua2, Yi-Lin Yang1, Ting-Ting Shi1, Wei Liu1, Xiu Tuo1, Yu Li3, Xi Cao1, Fang-Yuan Yang1.
Abstract
BACKGROUND: The pathogenesis Graves' Orbitopathy (GO) is not yet fully understood. Here, we conducted a pathway analysis based on genome-wide DNA methylation data of Chinese GO patients to explore GO-related pathways and potential feature genes.Entities:
Mesh:
Year: 2019 PMID: 30733969 PMCID: PMC6348866 DOI: 10.1155/2019/9565794
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Characteristics of case and control subjects.
| Age | Sex | Height | Weight | Duration | CAS | TRAb | |
|---|---|---|---|---|---|---|---|
| (year) | (M/F) | (cm) | (cm) | (months) | (U/L) | ||
| Case 1 | 57 | M | 175 | 86 | 6 | 3 | 2.14 |
| Case 2 | 55 | M | 172 | 85 | 1 | 4 | 11.39 |
| Case 3 | 54 | M | 172 | 70 | 3 | 4 | 6.92 |
| Case 4 | 61 | M | 175 | 80 | 2 | 2 | 5.13 |
| Case 5 | 47 | M | 172 | 70 | 6 | 3 | 3.37 |
| Case 6 | 53 | M | 162 | 64 | 11 | 5 | 5.3 |
| Control 1 | 46 | M | 171 | 77 | <1.75 | ||
| Control 2 | 48 | M | 176 | 72 | <1.75 | ||
| Control 3 | 52 | M | 175 | 72 | <1.75 | ||
| Control 4 | 54 | M | 168 | 65 | <1.75 | ||
| Control 5 | 50 | M | 169 | 80 | <1.75 | ||
| Control 6 | 49 | M | 165 | 79 | <1.75 |
CAS: Clinical Activity Score.
Figure 1The flowchart of the study. Firstly, the pathway analyses were performed to extract the significant pathways based on the DNA methylation profile of the differentially methylated regions (DMRs). Secondly, for each significant pathway, the Methylation-based Inference of Regulatory Activity (MIRA) scores were calculated to infer the regulatory activity of genes involved in the pathway. Finally, the genes involved in the significant pathways were taken as the subsets, and random forest method was applied to these gene subsets to classify samples and to extract GO-related feature genes. DMRs: differentially methylated regions. MIRA: Methylation-based Inference of Regulatory Activity.
The extracted significant pathways.
| Pathway Name | KEGG ID | The number of genes involved in the pathway | p-value |
|---|---|---|---|
| Toxoplasmosis | hsa05145 | 10 | <0.001 |
| Axon guidance | hsa04360 | 10 | <0.001 |
| Focal adhesion | hsa04510 | 11 | <0.001 |
| Proteoglycans in cancer | hsa05205 | 13 | 0.007 |
Figure 2Four significant pathways with GO. (a) The distribution of the counts of genes in three clusters in toxoplasmosis pathway between GO patients and normal controls. (b) The distribution of the counts of genes in three clusters in Axon guidance pathway between GO patients and normal controls. (c) The distribution of the counts of genes in three clusters in focal adhesion pathway between GO patients and normal controls. (d) The distribution of the counts of genes in three clusters in Proteoglycans in cancer pathway between GO patients and normal controls. (e) A Venn diagram to show the number of overlapped genes shared by four significant pathways.
Figure 3MIRA scores of genes involved in significant pathways between GO patients and normal controls. (a) Toxoplasmosis pathway. (b) Axon guidance pathway. (c) Focal adhesion pathway. (d) Proteoglycans in cancer pathway. MIRA: Methylation-based Inference of Regulatory Activity.
Figure 4The Focal adhesion pathway in KEGG graph. Genes showing lower methylation level in GO patients were highlighted in pink colors whereas genes showing higher methylation in GO patients were highlighted in orange colors.
Figure 5GO-related feature genes extracted by random forest method. In each significant pathway, we extracted those genes whose MDG ranked the top 5 in all of 12 models as GO-related feature genes. (a) Feature genes involved in toxoplasmosis pathway. (b) Feature genes involved in Axon guidance pathway. (c) Feature genes involved in focal adhesion pathway. (d) Feature genes involved in Proteoglycans in cancer pathway.